Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd vs standard chemotherapy as adjuvant therapy for HER2-expressing endometrial carcinoma
CTR20253443Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in endometrial cancer (EC), sponsored by Daiichi Sankyo Co., Ltd.. Started Jan 2026; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20253443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253443.